**BACKGROUND**

Italy is one of the European countries where Risk Sharing Scheme between healthcare institutions and pharmaceutical companies has been widely implemented. It is a new model proposed to accelerate the registration and the availability on the market of a new drug. Since September 2007, the Italian drug agency has developed a web register to include data for patients' monitoring who receive medicines under a Risk Sharing Scheme: the physician prescribes medicines from a list of high-cost oncology drugs and the Italian drug agency validates each prescription and e-mails the hospital pharmacy to release the drug.

The nonresponder patients are documented in the web register by health authorities and the pharmacist applies for pay-back to the pharmaceutical company.

Since 2011, Sicily Region has had a hospital pharmacist as an official figure in each pharmacy department involved in clawing back refunds from manufacturers for undocumented nonresponder patients and to complete the pay-back procedures.

**PURPOSE**

To quantify the amount of refunds clawed back from manufacturers after the pharmacist's implementation.

**METHODS**

We detected and examined unresponder patients registered in Registro AIFA-onco. Besides we completed the pay-back procedures.

The ex-factory expense was € 6,340,011.66: € 431,063.89 recovered, € 145,678.92 waiting for reimbursement and € 136,220.50 with denied reimbursement.

**RESULTS**

The number of the registered patients increased of 83%

The number of documented patients was recorded: 190 Erlotinib, 103 Sorafenib, 57 Sunitinib, 38 Lapatinib, 14 Everolimus, 1 Pemetrexed , 20 Bevacizumab, 20 Cetuximab, 12 Gefitinib , 2 Vinflunina, 16 Lenalidomide, 3 thalidomide, 1 Panitumumab, 7 Bortezomib, 4, Azacitidine, 3 Trabectedin.

**CONCLUSIONS**

The pharmacist’s implementation allows the complete availability of pay-back procedures and a reliable assessment of responder and nonresponder patients.

**BIBLIOGRAPHY**

1. http://monitoraggio-farmaci.agenziafarmaco.it
2. D.A. Sicily n.249-15/02/2011 “Piano annuale dei controlli”,
3. An italian model to evaluate appropriateness and effectiveness of drugs. A. Palazzo,
4. Risk-sharing schemes: the Italian experience in the field of rare cancers. Luca De Negro.